Search results

Search:
in the keywords: BETA-AMYLOID

Sort By:

Limit search:

Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system

100%

Hauff K., Zamzow C., Law W. J., De_Melo J., Kennedy K., Los M.

Archivum Immunologiae et Therapiae Experimentalis

2005

vol. 53

issue 4

308-320

In this review we focus on peptide- and peptidomimetic-based approaches that target autoimmune diseases and some pathologies of the central nervous system. Special attention is given to asthma, allergic rhinitis, osteoarthritis, and Alzheimer's disease, but other related pathologies are also reviewed, although to a lesser degree. Among others, drugs like Diacerhein and its active form Rhein, Pralnacasan, Anakinra (Kineret), Omalizumab, an anti-beta chain antibody 'BION-1', are described below as well as attempts to target beta-amyloid peptide aggregation. Parts of the review are also dedicated to targeting of pathologic conditions in the brain and in other tissues with peptides as well as methods to deliver larger molecules through the 'blood-brain barrier' by exploring receptor-mediated transport, or elsewhere in the body by using peptides as carriers through cellular membranes. In addition to highlighting current developments in the field, we also propose, for future drug targets, the components of the inflammasome protein complex, which is believed to initiate the activation of caspase-1 dependent signaling events, as well as other pathways that signal inflammation. Thus we discuss the possibility of targeting inflammasome components for negative or positive modulation of an inflammatory response.

Alzheimer's beta-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects

58%

Pogocki D.

Acta Neurobiologiae Experimentalis

2003

vol. 63

issue 2

131-145

This mini review gives a brief overview over the oxidation mechanism of methionine (Met), relevant for processes which may lead to the oxidation of amyloid beta-peptide (betaAP), involved in the pathogenesis of Alzheimer?s disease. The Cu II-catalysed oxidation of C-terminal Met 35 in AP depends on the secondary structure of the peptide. That seems to be the key to the known propensities of this peptide to form reactive oxygen species and free radicals. The pro-oxidant character of betaAP is not associated with its -beta sheet insoluble form. On the contrary, the alpha-helically organised structure is responsible for betaAP redox-related cytotoxicity.

Refine search results

1 Acta Neurobiologiae Experimentalis

1 Archivum Immunologiae et Therapiae Experimentalis

1 2005

1 2003

1 De_Melo J.

1 Hauff K.

1 Kennedy K.

1 Law W. J.

1 Los M.

1 Pogocki D.

1 Zamzow C.

Search results

Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system

Alzheimer's beta-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects